A new analysis looked at whether breviscapine helps people with coronary heart disease and angina. This is a condition where the heart does not get enough blood flow, causing chest pain.
The researchers combined results from multiple studies. They compared breviscapine, given alone or with usual treatment, to usual treatment alone. The main measure was how many people improved overall.
People who took breviscapine were about 20% more likely to see improvement compared to those who only received usual care. The analysis found this result was consistent across the studies.
However, the analysis did not report information about side effects, serious problems, or how many people stopped treatment. It also did not say how long patients were followed or what other outcomes were measured.
Because safety data is missing, patients and doctors should be careful. More research is needed to fully understand the benefits and risks of breviscapine for heart disease and angina.
Common questions
What is breviscapine used for?
Breviscapine is being studied for coronary heart disease with angina. In this meta-analysis, it was given alone or added to conventional therapy. The review found a higher total effective rate with breviscapine, but it did not report what conditions or symptoms improved. Always ask your doctor if breviscapine is right for you.
How effective is breviscapine for angina?
The meta-analysis reported a risk ratio of 1.20 (95% CI 1.14 to 1.26) for total effective rate. That means people taking breviscapine were about 20 percent more likely to be classified as responding to treatment. However, the review did not describe how response was measured or how long patients were followed.
Is breviscapine safe? What are the side effects?
The provided analysis does not report any safety information. There are no details on side effects, serious adverse events, or discontinuations. Without this information, it is not possible to say whether breviscapine is safe. Talk with your doctor about any concerns before starting or changing treatment.
Who was included in this breviscapine meta-analysis?
The review included patients with coronary heart disease and angina pectoris. The total number of patients was not reported. The studies compared breviscapine, alone or as an add-on, with conventional therapy. No other details about the participants, such as age or other health conditions, were provided.
